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Abstract
Background: Amyloid beta (Ab) is the main agent responsible for the advent and progression of Alzheimer’s
disease. This peptide can at least partially antagonize nerve growth factor (NGF) signalling in neurons, which may
be responsible for some of the effects produced by Ab. Accordingly, better understanding the NGF signalling
pathway may provide clues as to how to protect neurons from the toxic effects of Ab.
Results: We show here that Ab activates the RhoA GTPase by binding to p75NTR, thereby preventing the NGF-
induced activation of protein tyrosine phosphatase 1B (PTP1B) that is required for neuron survival. We also show
that the inactivation of RhoA GTPase and the activation of PTP1B protect cultured hippocampal neurons against
the noxious effects of Ab. Indeed, either pharmacological inhibition of RhoA with C3 ADP ribosyl transferase or the
transfection of cultured neurons with a dominant negative form of RhoA protects cultured hippocampal neurons
from the effects of Ab. In addition, over-expression of PTP1B also prevents the deleterious effects of Ab on cultured
hippocampal neurons.
Conclusion: Our findings indicate that potentiating the activity of NGF at the level of RhoA inactivation and PTP1B
activation may represent a new means to combat the noxious effects of Ab in Alzheimer’s disease.
Background
According to the amyloid hypothesis, amyloid beta (Ab)
aggregates form deposits in the brain, the process that
precipitates the different manifestations of Alzheimer’s
disease (AD) [1]. Consequently, most therapeutic
approaches to treat AD centre on this peptide: on the
one hand attempting to limit the production of Ab or
the formation of fibrils and aggregates [2,3], while on
the other hand, favouring its clearance. Therapeutic
approaches aimed at clearing Ab plaques have received
special attention, and methods for active or passive
immunisation have proven effective in reducing Ab con-
tent in the brain. Nevertheless, these strategies have
failed to conclusively ameliorate or retard cognitive
deterioration in AD patients [4,5].
Another approach that could be considered involves
blocking the signals induced by Ab that provoke neuro-
nal death. However, despite extensive studies into the
effects of Ab on neurons, our understanding of Ab sig-
nalling remains fragmented, and a consistent framework
for such processes has yet to be defined. Still, recent
publications have reinforced the notion that Ab inter-
feres with insulin signalling [6] and indeed, when soluble
forms of Ab bind to dendrites, they provoke the removal
of insulin receptors (probably by activating their interna-
lization), as well as preventing synapse formation [7]. In
addition, intracellular Ab may impair insulin signalling
by preventing phosphoinositide-dependent kinase
dependent activation of Akt [8]. This Ab-promoted dis-
ruption of insulin signalling has prompted clinical trials
in which insulin activity is primed and stimulated [9,10].
By contrast, Ab neurotoxicity has also been associated
with the trophic effects of NGF. Indeed, some therapeutic
approaches for AD involve the use of NGF or mimic the
effects of NGF [11-16]. Indeed, the cellular and molecular
bases underlying the antagonism of NGF by Ab were
recently elucidated in part. Ab competes with NGF for
binding to p75NTR [17,18], thereby preventing the activa-
tion of NF--B by impairing the tyrosine phosphorylation
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and subsequent degradation of I--B [19]. The inhibition
of NF--B promoted by Ab results in the downregulation
of Homologous of Enhancer-of-split 1 (Hes1) expression, a
gene that has an important influence on dendrite pat-
terning and GABAergic inputs [20,21].
In this study, we show that Ab impairs the initial steps
of NGF signalling at the level of the RhoA GTPase and
PTP1B. We also show that potentiating NGF signalling
by inhibiting RhoA GTPase and activating PTP1B offers
cells certain resistance against Ab neurotoxicity.
Results
Ab (1-42) induces morphological changes and regulates
neuron survival via p75NTR/RhoA
Previous studies revealed that Ab binds to p75NTR
receptors [17,18], and more recent data indicates that
p75NTR mediates the toxic effects of amyloid on choli-
nergic neurons [22,23]. Our earlier studies [19] showed
that Ab may specifically influence the morphology, gene
expression and survival of cultured hippocampal neu-
rons. Indeed, exposure of these neurons to Ab (5 μM
for 16 h) increased the number of primary dendrites
they emitted, while restricting their length (Figure 1A, B
and 1C). However, when the intracellular activity of
p75NTR was specifically uncoupled by incubating these
neurons with TAT-pep5 (1.0 μM) [24,25], the influence
of Ab on the neurons’ morphology was abolished
(Figure 1A, B and 1C). Accordingly, Ab no longer caused
an increase in dendrite number nor did it diminish their
length in the presence of TAT-pep5. We also showed
previously that the expression of Hes1 mRNA decreases
when hippocampal neurons are exposed to Ab (5 μM for
4 h: Figure 1D). Since Hes1 mRNA transcripts augment
in the presence of NGF (100 ng/ml) [20], the loss of
these transcripts suggests that amyloid reverses the
effects of NGF [19]. In accordance with the morphologi-
cal effects observed in these neurons, pharmacological
inhibition of p75NTR signalling with TAT-pep5 prevented
Ab from inhibiting Hes1 expression. This is particularly
significant because Hes1 over-expression protects cells
against the deleterious effects of Ab, and preventing the
decrease of Hes1 expression improves the survival of neu-
rons exposed to Ab (Chacon et al., unpublished results).
Perhaps most importantly, application of TAT-pep5 (1.0
μM) protected hippocampal neurons from the death
induced by prolonged exposure to Ab (5 μM for 90 h:
Figure 1E and 1F). Thus, these data indicate that by inter-
acting with the p75NTR/RhoA signalling pathway, Ab
combats the positive effects of NGF in terms of morphol-
ogy, gene expression and survival.
The role of RhoA in the neurotoxicity of Ab
Since TAT-pep5 prevents p75NTR from associating with
Rho-GDI intracellularly, thereby blocking its ability to
activate RhoA GTPase [24,25], we assessed to what
extent RhoA might mediate the effects of Ab. In cul-
tured PC12 nnr5 cells (cells devoid of TrkA), activated
RhoA was largely increased within 2 h of exposure to
Ab (5 μM) (Figure 2A). By contrast, incubation with
NGF (100 ng/ml for 5 h) hardly decreased the levels of
activated RhoA, probably because such levels were
already low in this experimental system. However, the
addition of NGF prevented the activation of RhoA
induced by Ab (5 μM for 2 h). These results suggested
that the activation of RhoA induced by Ab through
p75NTR may be important for Ab to influence the mor-
phology and survival of cells. To test this hypothesis, we
studied the role of RhoA in mediating the effects of Ab
on dendrite patterning. Thus, the transfection of hippo-
campal neurons with a dominant negative form of
RhoA, RhoA N19 [26], counteracted the effects of Ab
on dendrite patterning (Figure 2B, C and 2D). When
specific parameters of dendrites were quantified (Figure
2C and 2D), Ab failed to decrease dendrite length or
increase the number of primary dendrites when the
activity of RhoA was abrogated by transfection of the dn
form of this GTPase. By contrast, activation of RhoA for
16 h by applying 200 ng/ml CNFy to cultured neurons
[27] produced changes in dendrite patterning, such as a
decrease in dendrite length and an increase in dendrite
number (Figure 2E and 2F). Further evidence that the
inhibition of RhoA to some extent interrupted Ab sig-
nalling in neurons was obtained when neurons were
treated with a cell permeable form of the C3 ADP ribo-
syl transferase (1.0 μM, 18 h). Inhibition of RhoA pre-
vented Ab from impeding Hes1 expression (Figure 2G)
in a similar manner to the effects of TAT-pep5 on
neurons (Figure 1D).
RhoA GTPase not only exerts an important influence
on neuron morphology but also, on survival of neurons
treated with Ab. Indeed, inhibition of RhoA partially
protected neurons against the noxious effects of Ab and
transfection of the dn form of RhoA also increased the
cells’ resistance to Ab neurotoxicity (Figure 3A and 3B).
Likewise, prior exposure of the cultured neurons to C3
ADP ribosyl transferase (1.0 μM) made neurons resis-
tant to Ab (5 μM: Figure 3C), further evidence of the
role of RhoA in Ab induced neuron death. However,
treating neurons with CNFy for 90 h did not produce
cell death (data not shown), indicating that the noxious
effects of Ab are not exclusively mediated by RhoA.
Protein tyrosine phosphatase 1B activity protects neurons
against Ab neurotoxicity
It is thought that PTP1B activity was controlled by the
RhoA GTPase, although the precise mechanism involved
remains unknown [28]. Since NGF increases PTP1B
activity by binding to p75NTR [29], we tested whether
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Figure 1 TAT-pep5 specifically uncouples p75NTR from the RhoA GTPase, and it counteracts the effects of Ab on dendrite patterning,
gene expression and the survival of cultured hippocampal neurons. (A, B and C) E17 hippocampal neurons were plated at a density of
40,000 cells/cm2 and cultured for 7 DIV. Neurons were transfected with pEGFP and then exposed for a further 16 h to TAT-Pep5 (1.0 μM), Ab (5
μM), or both. The cells were fixed and labelled with the anti-EGFP antibody, and then processed for immunofluorescence. (A) representative
micrographs of cultured neurons under the different conditions. The relative dendrite length (B) and primary dendrite numbers (C) was
quantified as indicated in the methods section. Note that TAT-pep5 reversed the effects of Ab on dendrite length and number. (D) Neurons
cultured for 7 DIV (40,000 cells/cm2) were first incubated with TAT-Pep5 (1.0 μM) for 18 h, after which they were stimulated with Ab (5 μM) for 4
h, lysed and then processed for real time PCR to quantify Hes1 expression. Note that TAT-pep5 prevented the Ab-induced decrease in Hes1
mRNA. (E) 7 DIV cultures (30,000 cells/cm2) were stimulated with TAT-pep5 (1.0 μM) and/or Ab (5 μM) for 90 h. The neurons were then stained
with DAPI and those with intact nuclei were counted. Note that TAT-pep5 rescued around half of the neurons from the deleterious effects of
Ab. (F) Representative micrographs of DAPI stained nuclei in cultured hippocampal neurons treated with Ab, or with Ab and TAT-pep5, the latter
conferring resistance against Ab.
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Figure 2 Ab activates RhoA thereby influencing neuron morphology. (A) Western blots showing the activated and total RhoA GTPase in
extracts from cultured PC12 nnr5 cells stimulated with NGF (100 ng/ml) for 5 h at the times indicated, or with Ab (5 μM). Note that in contrast
to NGF, Ab increased the levels of RhoA GTP. The quantification of RhoA GTP in the lower panel is an average from four independent
experiments. (B) Representative micrographs of hippocampal neurons cultured for 7 DIV (40,000 cells/cm2), treated with Ab (5 μM) and/or co-
transfected with EGFP and a myc tagged RhoA N19 (a dn form of RhoA) for 16 h. (C, D) Quantification of relative dendrite length (C) and
primary dendrite number (D) in the four conditions indicated. Note that the attenuation of RhoA GTPase activity counteracted the effects of Ab
on dendrite length and number. Also note in (C) that the attenuation of RhoA activity increased the length of dendrites per se. (E, F)
Quantification of relative dendrite length (E) and primary dendrite number (F) in cultured neurons after addition of CNFy (200 ng/ml: a specific
activator of RhoA) for 16 h. (G) 7 DIV neurons in culture were first incubated with C3 ADP rybosyl transferase (1.0 μM) for 18 h, they were
stimulated with Ab (5 μM) for 4 h, lysed and then processed for real time PCR to quantify Hes1 expression. Note that the inhibition of RhoA by
C3 prevented the Ab-induced decrease in Hes1 mRNA.
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PTP1B might participate in Ab signalling in hippocam-
pal neurons. Indeed, while NGF (100 ng/ml) increased
the activity of PTP1B four-fold, Ab (5 μM) failed to do
so (Figure 4A). Moreover, prior application of Ab to
cultured hippocampal neurons prevented NGF from
activating this phosphatase (Figure 4B). When PTP1B
activity was assessed in extracts from cells grown under
different conditions, it was at least partially controlled
by RhoA. Thus, the treatment of neurons with the selec-
tive activator of the RhoA GTPase, CNFy (200 ng/ml)
[27], also prevented NGF from activating the phospha-
tase (Figure 4B). Since the activation of RhoA by either
Ab or CNFy prevented PTP1B activation, we concluded
that RhoA is a negative regulator of the phosphatase. In
Figure 3 The role of RhoA in Ab induced neuron death. (A, B)
Hippocampal neurons (30,000 cells/cm2) were cultured for 7 days
and then treated with Ab (5 μM). Two days later the neurons were
transfected with the dn RhoA N19 and on the following day, the
cells were stained and the number of live cells were determined as
described in the Methods. (A) Representative micrographs of
double-labelled cultured hippocampal neurons under the four
conditions described. Green represents EGFP immunostaining, red is
the transfected myc-tagged RhoA N19 and the DAPI stained nuclei
are blue. (B) Quantification of live cells. Note that transfection with
the dominant negative form of RhoA rescued a significant number
of neurons from Ab-induced death. (C) The effects of Anti-amyloid
were more dramatic when C3 ADP ribosyl transferase (1 μM), a
RhoA inhibitor, was applied to the cultures. Cultured hippocampal
neurons (7 DIV) were treated simultaneously with C3 ADP ribosyl
transferase and Ab, and the number of live cells was determined
four days later in culture.
Figure 4 Amyloid b interferes with the capacity of NGF to
activate protein tyrosine phosphatase 1B in hippocampal
neurons. Cultured 7 DIV neurons (about 250,000 cells per
experimental point) were treated as indicated and PTP1B activity
was assessed. (A) Whereas NGF (100 ng/ml) increased PTP1B activity
several fold, Ab (5 μM) did not alter the activity of the phosphatase,
although Ab did prevent the increase of PTP1B activity induced by
NGF (B). Another activator of RhoA activity, CNFy (200 ng/ml), also
prevented the activation of PTP1B caused by NGF. Both Ab and
CNFy were applied to cultures 18 h before stimulating with NGF for
4 h. (C) The inhibition of RhoA activity after incubating the cells
with either C3 (1 μM) or TAT-pep5 (1 μM) for 18 h increased the
activity of PTP1B. By contrast to NGF, such increases were not
counteracted by prior application of Ab.
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fact, inhibiting RhoA with C3 ADP rybosyl transferase
was sufficient to increase PTP1B activity, which interest-
ingly could not be prevented by amyloid. Furthermore,
application of TAT-pep5 to the cultured neurons also
increased PTP1B activity and again, this was not pre-
vented by Ab (Figure 4C). Together, these results
demonstrate that PTP1B activity was mediated by
p75NTR/RhoA and more specifically, that p75NTR, a
receptor for both NGF and Ab, plays an important role
in the regulation of this phosphatase.
The effect of Ab on PTP1B was further evident when
the morphology and survival of neurons over-expressing
PTP1B was studied. In terms of morphology, overex-
pression of PTP1B mimics the effects of NGF on den-
drite patterning [20] and most importantly, it
counteracts the effects of Ab. The overexpression of
PTP1B increased the length of dendrites and counter-
acted the shortening of dendrites caused by Ab (Figure
5A and 5B). In addition, the increase in dendrite num-
ber when neurons were exposed to Ab was prevented in
neurons overexpressing PTP1B (Figure 5A and 5C).
However, the effects of PTP1B activity on survival were
even more dramatic, as overexpression of PTP1B res-
cued about half of the neurons from the death caused
by Ab (Figure 5D and 5E). Taken together these results
demonstrate that neurons require an active form of
PTP1B to survive. Furthermore, these data also indicate
that impairment of NGF by Ab induces PTP1B activa-
tion, which plays an important role in the induction of
neuron death by Ab.
Discussion
The effects of Ab on cultured neurons mediated by
p75NTR
The noxious effects of Ab appear to be at least partially
due to the neutralisation of NGF activity in neurons
[19] (see also [30]) and indeed, we demonstrated that
Ab prevents the activation of NF--B and the increase
of Hes1 expression caused by NGF. We also more
recently revealed novel features of NGF signalling in
neurons, including the activation of PTP1B after binding
to p75NTR [29], that is in turn necessary for the tyrosine
phosphorylation and degradation of I--B, and the sub-
sequent activation of NF--B. p75NTR appears to be the
only receptor mediating the effects of NGF on both
RhoA and PTP1B. Indeed, we showed that a selective
blockage of the receptor prevented NGF-induced PTP1B
activation and that the inactivation of TrkA did not
abolish such an effect [29].
The participation of p75NTR in the activity of Ab is
well documented, and radioactive Ab was seen to bind
to the receptor and trigger apoptosis in cell lines that
overexpress p75NTR [17,18]. More recently, neurons
expressing a mutated form of p75NTR devoid of its
Figure 5 Overexpression of PTP1B counteracts the effects of
Ab on dendrite patterning (A, B, C) and neuron death (D, E).
Cultured hippocampal neurons (40,000 cells/cm2, 7 DIV) were co-
transfected with the EGFP and PTP1B plasmids, treated with Ab (5
μM) and incubated for a further 16 h to analyse dendrite patterning
(A, B, C). (A) Representative micrographs of cultured hippocampal
neurons at 7 DIV treated with Ab and/or transfected with PTP1B.
EGFP immunostaining is in green and the transfected HA-tagged
PTP1B in red. (B, C) Quantification of the relative dendrite length (B)
and primary dendrite number (C) in the four conditions indicated.
Note that overexpression of PTP1B increased dendrite length and
prevented the morphological effects of Ab. (D, E) Hippocampal
neurons (30,000 cells/cm2) were cultured for 7 days and then
treated with Ab (5 μM). Two days later, the neurons were
transfected with the PTP1B expressing plasmid, and on the
following day the cells were stained and the live cells determined
as described in the Methods. (D) Representative micrographs of
double-labelled cultured hippocampal neurons under the four
conditions described. EGFP immunostaining is in green, the
transfected HA-tagged PTP1B in red and the DAPI stained nuclei are
blue. (E) Quantification of live cells. Note that transfection with the
PTP1B expressing plasmid rescued a significant number of neurons
from Ab-induced neuron death.
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extracellular domain were shown to be resistant to the
neurite dystrophy associated to c-Jun activation and to
apoptosis, both in vitro and in vivo [23,31]. In addition,
the fact that Ab augments the expression of p75NTR in
SH-SY5Y human neuroblastoma cells is further evidence
for the role of p75NTR, especially given that it also
increases in hippocampal neurons from a transgenic
mouse model of AD [32].
In a PC12 cell variant devoid of TrkA, we established
that Ab activates RhoA by binding to p75NTR, an effect
that is partially prevented by exposing the cells to NGF
prior to the administration of Ab. Activation of RhoA
by Ab has also been observed in SH-SY5Y cells, in
which it controls the phosphorylation of the collapsing
response mediator protein-2, an effect that disrupts its
binding to b-tubulin and neurite growth prior to cell
death [33].
The role of RhoA GTPase in neurodegeneration
There is increasing evidence that RhoA is an essential
effector of certain neurodegenerative processes. The
binding of various myelin associated ligands to the
Nogo receptor complex, which includes p75NTR, pro-
duces RhoA activation [34]. Moreover, disruption of this
receptor’s function or deactivation of RhoA facilitates
neurite and axonal growth in injured CNS neurons
[35,36]. RhoA activity has also been associated to AD,
particularly since the distribution of RhoA is altered in
the brains of AD patients and in an AD mouse model.
Moreover, activated RhoA augments in dystrophic den-
drites and diminishes around synapses [37]. Here, we
reveal that activation of RhoA not only decreases
dendrite length but also, it is an important mediator of
Ab-induced neuron death. Indeed, activation of RhoA
by CNFy mimics the effects of Ab on dendrite morphol-
ogy, although it did not mimic the deleterious effects of
Ab on the cells. Nevertheless, the role of RhoA in neu-
ronal death was assessed since attenuating the GTPase
activity, either by transfecting neurons with a dn form
of RhoA or through pharmacological inhibition with C3
ADP ribosyl transferase, protects a significant number of
neurons from Ab neurotoxicity. These results indicate
that RhoA activation plays a role in AD development,
suggesting that inhibition of this GTPase might delay
the progress of the disease.
Relationship between RhoA and PTP1B
A functional analysis revealed that constitutively active
RhoA inactivates PTP1B, although the precise mechan-
ism underlying such inhibition remains unknown [28].
Our studies demonstrate a functional relationship
between these two enzymes, since the pharmacological
inhibition of RhoA was followed by activation of
PTP1B, thereby mimicking the effects of NGF on the
phosphatase. Conversely, the activation of RhoA by
CNFy, a yersinia toxin [27] prevented NGF from activat-
ing PTP1B, an effect reminiscent of the action of Ab.
However, activation of RhoA did not diminish PTP1B
activity below basal levels and the activation of RhoA
only reduced the fraction of PTP1B activity increased by
NGF. This may indicate that not all PTP1B molecules
are functionally linked to the state of RhoA activation,
reflecting the variety of signalling pathways in which
PTP1B is involved [38].
RhoA controls dendrite length and hampers dendrite
elongation, spine formation and synapse stabilization by
a mechanism in which the activation of ROCK is
involved [39]. The fact that RhoA also governs dendrite
patterning by mechanisms that don’t involve PTP1B
may explain how CNFy decreases dendrite length with-
out affecting the activity of the phosphatase. However,
the true nature of the RhoA/PTP1B connection still
remains unclear. Reasonable candidates to participate in
this process are the reactive oxygen species (ROS) and
indeed, early studies revealed that Ab increased the ROS
pool in neurons [40,41] reviewed in [42]. Increased
levels of ROS may act in several ways, activating RhoA
by oxidising a redox sensitive domain [43], or by inacti-
vating cysteine phosphatases like PTP1B, as seen in
vitro [44] and in cellular systems after calcium influx
[45], as well as after application of insulin [46], EGF
[47] or IL-4 [48].
Activation of PTP1B is needed for neuron survival
PTP1B is often constitutively active although its activity
may be negatively controlled by Akt induced serine
phosphorylation of the phosphatase [49], tyrosine phos-
phorylation [50], or extracellular stimulation of ROS
levels that oxidise the active centre of the phosphatase
under the control of extracellular effectors such as insu-
lin [51]. Activation of PTP1B activity is associated with
the C-terminal cleavage of the enzyme [52], reviewed in
[53]. However, activation of PTP1B associated to extra-
cellular stimuli such as NGF has only recently been
observed [29], and post-translational modifications of
the enzyme that enhance its activity have yet to be
identified.
Excess PTP1B activity is associated with important
pathologies such as type II diabetes, obesity [54,55] and
tumorigenesis [53], which has driven the search for
PTP1B inhibitors [56]. In particular, the impairment of
insulin signalling by uncontrolled PTP1B activity has
been correlated with the appearance of both type II dia-
betes and AD [57]. Thus, the use of PTP1B inhibitors
that strengthen insulin signalling may prevent at least
some of the problems associated with diabetes and
hopefully, the development of AD. However, our results
indicate that PTP1B lies in the NGF signalling pathway
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and that it is activated by this factor via RhoA inactivation.
PTP1B activity is needed for neuron survival and it
helps cultured hippocampal neurons resist the attack
of amyloid. Our early studies show that PTP1B may
activate the Src kinase, which is needed for NF--B
activation and Hes1 expression [29] (see Figure 6).
Therefore, it would interesting to evaluate the neurolo-
gical side-effects of the pharmacological inhibition of
PTP1B in animal models.
Conclusions
The mechanism by which we believe NGF promotes
Hes1 expression and by which Ab opposes such effects
is outlined in Figure 6 in which the main findings of the
present study are represented in red, our previous
results are in blue and other published findings are in
black. Thus, the main conclusions of the present studies
are: (i) Ab activates RhoA via p75NTR; (ii) the activation
of RhoA inactivates PTP1B; (iii) inactivation of RhoA by
either pharmacological inhibitor or transfection with a
dn isoform makes neurons resistant to Ab; (iv) increas-
ing PTP1B activity makes neurons overexpressing the
phosphatase resistant to Ab. In summary, by strengthen-
ing different elements in the NGF signalling pathway it
is feasible to make neurons more resistant to the effects
of amyloid.
Methods
Antibodies
For immunocytochemistry, the primary antibodies used
were a rabbit anti-enhanced green fluorescent protein
(EGFP) from Invitrogen (Carlsbad, CA; used at a dilu-
tion of 1:500), a rat anti-hemagglutinin (HA) mAb and a
mouse anti-Myc mAb (both used at a dilution of 1:400;
Roche Applied Science, Mannheim, Germany). Western
blots were probed with a mouse anti-RhoA (1:250; Santa
Cruz Biotechnology, Santa Cruz, CA) and a mouse anti-
PTP1B was used for immunoprecipitations (1:50; BD
Transduction Laboratories, Lexington, KY). The goat
anti-rabbit Cy2 (1:1000), goat anti-rat Cy3 (1:500), goat
anti-mouse Cy3 (1:1000) and donkey anti-mouse-HRP
(1:5000) secondary antibodies were all obtained from
Jackson Immuno Research (West Grove, USA).
Other Chemicals
NGF from mouse salivary glands was obtained from
Alomone Labs (Jerusalem, Israel), and it was used at a
concentration of 100 ng/ml. Amyloid b (1-42) was
obtained from NeoMPS (Strasbourg, France) and it was
used at a concentration of 5 μM. This peptide was dis-
solved in 1,1,1,3,3,3-hexafluoro-2-propanol to obtain the
oligomeric form of Amyloid b. After the solvent was
allowed to evaporate for 2 hrs at room temperature, the
peptide film was dissolved in DMSO, sonicated in a
water bath for 10 min diluted to 100 μM in PBS and
briefly vortexed, before it was incubated overnight at 4 °
C. Aliquots were stored at -20°C. C3 ADP ribosyl trans-
ferase (Cytoskeleton Inc., Denver, CO), a cell permeable
Rho inhibitor, was used at 500 ng/ml. CNFy (cytotoxic
necrotizing factor from Yersinia pseudotuberculosis), a
specific activator of RhoA, was produced as described
previously [27] and used at 200 ng/ml. Raytide™EL,
a general tyrosine kinase peptide substrate, and
TAT-Pep5, a cell permeable p75NTR signalling inhibitor
were used at 1.0 μM, each purchased from Calbiochem
(Darmstadt, Germany). [g-32P]ATP was obtained from
Perkin-Elmer (Madrid, Spain).
Transfection vectors
The EGFP expressing vector (pEGFP-N1) was obtained
from Clontech Laboratories, Inc. (Palo Alto, CA), while
the pCDNA 3.1 Zeo encoding a HA-tagged form of wild
type (wt) PTP1B was kindly provided by Carlos Arregui
(Buenos Aires, Argentina) [58]. The pRK5-Myc vector
encoding a Myc-tagged dominant negative form of
RhoA, RhoA N19 (Addgene plasmid 15901) [26], was
obtained from Addgene (Cambridge, MA).
Cell cultures
Primary hippocampal neuron cultures were prepared as
described previously [59], with some minor modifica-
tions. Briefly, the hippocampus was removed from E17
CD1 mouse foetuses and dissociated into single cells
following trypsin (Worthington, Lakewood, USA) and
DNase I digestion (Roche Applied Science). Neurons
were plated on glass coverslips or in plastic dishes
coated with poly-L-lysine (Sigma-Aldrich, Madrid,
Spain), and cultured in Neurobasal A supplemented
with 2 mM GlutaMAX I, 100 units/ml penicillin and
100 μg/ml streptomycin (Gibco BRL, Crewe, UK). After
7 days in vitro (DIV) the neurons were exposed to Ab,
NGF, and/or the pharmacological agents indicated.
Figure 6 Diagram showing the signals transduced by NGF
leading to Hes1 expression and neuron survival, and their
impairment by Ab. Various steps have been defined here and are
shown in red (labelled as 2). The steps in black ((3), (4), (5) and (6))
come from the literature and the steps labelled in blue (1 and 7)
are from our previous studies [19-21,29].
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TrkA-deficient PC12 cells, PC12nnr5 [60], were grown
in Dulbecco’s modified Eagle’s medium (DMEM) sup-
plemented with 5% heat-inactivated foetal bovine serum
(FBS), 10% heat-inactivated horse serum (Sigma-
Aldrich), 2 mM GlutaMAX I, 100 units/ml penicillin
and 100 μg/ml streptomycin (Gibco BRL). All cultures
were kept at 37°C in a humidified atmosphere contain-
ing 5% CO2.
Neuron transfection
Cultured neurons were transfected at 7 DIV with differ-
ent vectors using the Effectene Transfection Reagent
(Qiagen GmbH, Hilden, Germany) according to a modi-
fied version of the manufacturer’s instructions. Briefly,
0.6 μg of DNA was added to 120 μl of the EC buffer
and 3.5 μl of the Enhancer for each 35 mm cell culture
dish of hippocampal neurons. The solution was incu-
bated for 5 min at room temperature before 10 μl of
Effectene was added, and after a further 15 min incuba-
tion at room temperature, the final solution was added
to hippocampal neurons. The medium was then chan-
ged after 3 h.
Immunocytochemistry, image acquisition and the
morphometric analysis of labelled hippocampal neurons
At 16 h after transfection, the neurons were fixed for 30
min in 4% paraformaldehyde (PFA) prepared in PBS,
they were then permeabilized for 15 min at room tem-
perature with 0.5% Triton X-100 in PBS and blocked
with 10% FBS in PBS containing 0.1% Triton X-100.
The cells were incubated with the primary and second-
ary antibodies and the images of 10-20 neurons per cov-
erslip were acquired digitally using a 63× oil immersion
objective (Zeiss, Oberkochen, Germany). To analyze the
dendrites, a region of interest (ROI) with a radius of 50
μm was projected onto EGFP-labelled neurons, its cen-
tre roughly coinciding with the centre of the soma. The
dendrite length was expressed as the fraction of the den-
dritic tree that exceeds the limit of the ROI (fraction
dendrites >50 μm). In co-transfection experiments, only
double-labelled cells were analysed, which represented
more than 90% of the single-labelled cells.
Cell Survival
After treatment, the neurons were fixed for 30 min in
4% paraformaldehyde (PFA) in PBS and their nucleus
was stained with the fluorescent dye, 4’,6-diamidino-2-
phenylindole (DAPI: Sigma-Aldrich). Non-viable neu-
rons were recognized by nuclear condensation and/or
the fragmentation of their chromatin. The number of
viable neurons was counted in triplicate from ca. 50
fields in two independent experiments. In co-transfec-
tion experiments, only the nuclei of double-labelled cells
were analysed.
RhoA activation
To assay RhoA activation we followed a procedure
described elsewhere [25]. Briefly, stimulated PC12nnr5
cells were first lysed in buffer: 50 mM Tris [pH 7.5],
500 mM NaCl, 10 mM MgCl2, 1.0% Triton X-100, 0.5%
sodium deoxycholate, 0.1% SDS and a protease inhibitor
cocktail (Roche Applied Science, Mannheim, Germany).
The cleared lysates were incubated for 1 h at 4°C with
Rhotekin-conjugated agarose beads (Cytoskeleton), and
the beads were then collected by centrifugation and
washed with the lysis buffer. Activated RhoA was
detached from the beads by boiling for 5 minutes in
Laemmli reducing buffer, after which it was immediately
resolved by 12% SDS-PAGE and transferred to a nitro-
cellulose membrane. After blocking, the membranes
were probed overnight at 4°C with a primary antibody
directed against RhoA, which was detected with an
HRP-conjugated secondary antibody that was visualised
by enhanced chemiluminescence (GE-Healthcare, Piscat-
away, NJ). The intensity of the bands was evaluated by
densitometry using ImageQuant software (GE-
Healthcare).
Protein phosphatase 1B assay
The PTP1B assay was performed essentially as described
previously [61], with minor modifications. Briefly, 7DIV
cultured hippocampal neurons (1 × 106 cells) were col-
lected and homogenized in RIPA buffer (50 mM Tris
[pH7.5], 150 mM NaCl, 2 mM EDTA, 1.0% Triton
X-100 and an anti-protease cocktail). Equal amounts of
protein were incubated for 2 h at 4°C with a mouse
anti-PTP1B mAb, and then 20 μl of protein G sepharose
was added and incubated for additional 2 h with agita-
tion. Immunoprecipitated complexes were washed twice
in RIPA buffer, once with the assay buffer (25 mM imi-
dazole [pH7.2], 0.1 mg/ml BSA, 10 mM DTT) and they
were then resuspended in 25 μl of assay buffer. The
phosphatase substrate Raytide was labelled at its unique
tyrosine residue with [g-32P]ATP as described previously
[62]. Assay mixtures (30 μl) containing the immunopre-
cipitated pellet and [32P]-labelled raytide (1 × 105 cpm)
were incubated for 2 h at 30°C and the reaction was ter-
minated by adding 750 μl of a charcoal mixture (0.9 M
HCl, 90 mM sodium pyrophosphate, 2 mM NaH2PO4,
4% vol/vol Norit A). After centrifugation, the radioactiv-
ity in 400 μl of the supernatant was measured by scintil-
lation counting. Blanks were determined by measuring
the free [32P]phosphate in reactions where the immuno-
precipitates were either boiled or omitted, and these
values were subtracted from the reaction values.
Quantitative real time polymerase chain reaction (PCR)
After treatment, the total RNA was extracted from
cultures at 7 DIV using the Illustra RNAspin Mini kit
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(GE-Healthcare) and first strand cDNA was prepared
from the RNA using the First Strand Synthesis kit (Fer-
mentas GmbH, St Leon-Rot, Germany). Quantitative
PCR was performed using the ABI Prism 7000 Sequence
Detector (Applied Biosystems, Weiterstadt, Germany)
and TaqMan probes. Primers for Hes1 and the house-
keeping gene GADPH (as a control) were selected as the
Assay-on-Demand gene expression products (Applied
Biosystems). All TaqMan probes were labelled with 6-
carboxy fluorescein (FAM) and real time PCR was per-
formed using the TaqMan Universal PCR Master Mix
according to the manufacturers’ instructions. Hes1
expression was normalized to the GAPDH expression.
Statistical analysis
Data are presented as the mean ± SEM and an unpaired
Student’s t-test was applied to determine the levels
of significance, denoted as *p < 0.05, **p < 0.01,
***p < 0.001. All experiments were repeated at least twice.
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